Lyra Therapeutics, Inc.
LYRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $13 | $5 | $3 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $13 | $5 | $3 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -1.5% | 14.3% | 378.2% | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 100% | 100% | 100% | -10,318.9% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -3,928.4% | -4,188.1% | -3,956.2% | -14,952.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -6,090.9% | -4,023.1% | -4,055.6% | -15,267.7% |
| EPS Diluted | -1.43 | -1.26 | -1.83 | -3.35 |
| % Growth | -13.5% | 31.1% | 45.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |